It is essential to clarify the role of PYY in the regulation of bone mass and strength because the use of PYY analogues in the treatment of obesity has the potential to cause long-term detrimental side-effects in the skeleton, including an increased risk of fracture. This evidence concerns the gene PYY and obesity due to melanocortin 4 receptor deficiency.